Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

Martin W.G. Brinkhof; Matthias Egger; Andrew Boulle; Margaret May; Mina Hosseinipour; Eduardo Sprinz; Paula Braitstein; François Dabis; Peter Reiss; David R. Bangsberg; Martin Rickenbach; Jose M. Miro; Landon Myer; Amanda Mocroft; Denis Nash; Olivia Keiser; Margaret Pascoe; Stefaan Van Der Borght; Mauro Schechter; Martin Brinkhof

doi:10.1086/522986

Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

Martin W.G. Brinkhof, Matthias Egger, Andrew Boulle, Margaret May, Mina Hosseinipour, Eduardo Sprinz, Paula Braitstein, François Dabis, Peter Reiss, David R. Bangsberg, Martin Rickenbach, Jose M. Miro, Landon Myer, Amanda Mocroft, Denis Nash, Olivia Keiser, Margaret Pascoe, Stefaan Van Der Borght, Mauro Schechter, Martin Brinkhof

Research output: Contribution to journal › Article › peer-review

84 Scopus citations

Abstract

We examined the incidence of and risk factors for tuberculosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the incidence of tuberculosis associated with highly active antiretroviral therapy was similar: the rate ratio for months 7-12 versus months 1-3 was 0.48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings.

Original language	English (US)
Pages (from-to)	1518-1521
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	45
Issue number	11
DOIs	https://doi.org/10.1086/522986
State	Published - Dec 1 2007
Externally published	Yes

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1086/522986

Fingerprint Dive into the research topics of 'Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries'. Together they form a unique fingerprint.

Cite this

Brinkhof, M. W. G., Egger, M., Boulle, A., May, M., Hosseinipour, M., Sprinz, E., Braitstein, P., Dabis, F., Reiss, P., Bangsberg, D. R., Rickenbach, M., Miro, J. M., Myer, L., Mocroft, A., Nash, D., Keiser, O., Pascoe, M., Van Der Borght, S., Schechter, M., & Brinkhof, M. (2007). Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clinical Infectious Diseases, 45(11), 1518-1521. https://doi.org/10.1086/522986

Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. / Brinkhof, Martin W.G.; Egger, Matthias; Boulle, Andrew; May, Margaret; Hosseinipour, Mina; Sprinz, Eduardo; Braitstein, Paula; Dabis, François; Reiss, Peter; Bangsberg, David R.; Rickenbach, Martin; Miro, Jose M.; Myer, Landon; Mocroft, Amanda; Nash, Denis; Keiser, Olivia; Pascoe, Margaret; Van Der Borght, Stefaan; Schechter, Mauro; Brinkhof, Martin.

In: Clinical Infectious Diseases, Vol. 45, No. 11, 01.12.2007, p. 1518-1521.

Research output: Contribution to journal › Article › peer-review

Brinkhof, MWG, Egger, M, Boulle, A, May, M, Hosseinipour, M, Sprinz, E, Braitstein, P, Dabis, F, Reiss, P, Bangsberg, DR, Rickenbach, M, Miro, JM, Myer, L, Mocroft, A, Nash, D, Keiser, O, Pascoe, M, Van Der Borght, S, Schechter, M & Brinkhof, M 2007, 'Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries', Clinical Infectious Diseases, vol. 45, no. 11, pp. 1518-1521. https://doi.org/10.1086/522986

Brinkhof, Martin W.G. ; Egger, Matthias ; Boulle, Andrew ; May, Margaret ; Hosseinipour, Mina ; Sprinz, Eduardo ; Braitstein, Paula ; Dabis, François ; Reiss, Peter ; Bangsberg, David R. ; Rickenbach, Martin ; Miro, Jose M. ; Myer, Landon ; Mocroft, Amanda ; Nash, Denis ; Keiser, Olivia ; Pascoe, Margaret ; Van Der Borght, Stefaan ; Schechter, Mauro ; Brinkhof, Martin. / Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. In: Clinical Infectious Diseases. 2007 ; Vol. 45, No. 11. pp. 1518-1521.

@article{1c5e4ed8d24d4a03b741d470ca48220d,

title = "Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries",

abstract = "We examined the incidence of and risk factors for tuberculosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the incidence of tuberculosis associated with highly active antiretroviral therapy was similar: the rate ratio for months 7-12 versus months 1-3 was 0.48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings.",

author = "Brinkhof, {Martin W.G.} and Matthias Egger and Andrew Boulle and Margaret May and Mina Hosseinipour and Eduardo Sprinz and Paula Braitstein and Fran{\c c}ois Dabis and Peter Reiss and Bangsberg, {David R.} and Martin Rickenbach and Miro, {Jose M.} and Landon Myer and Amanda Mocroft and Denis Nash and Olivia Keiser and Margaret Pascoe and {Van Der Borght}, Stefaan and Mauro Schechter and Martin Brinkhof",

note = "Funding Information: Potential conflicts of interest. M.M. has received travel grants from GlaxoSmithKline. P.R. has received research funding from Boehringer-In-gelheim and Merck and has received honoraria for speaking engagements or advisory board participation from Gilead Sciences, Boehringer-Ingel-heim, Roche, Tibotec, GlaxoSmithKline, and Theratechnologies. J.M.M. has received recent research funding or honoraria as speaker/consultant from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Chiron, Cubist, Merck, Novartis, GlaxoSmithKline, Gilead Sciences, Oxford Immunotec, Pfizer, Roche, and Theravance. A.M. has received a consultancy honorarium from Bristol-Myers Squibb. All other authors: no conflicts. Funding Information: Financial support. The ART-LINC Collaboration is funded by the US National Institutes of Health (Office of AIDS Research) and the French Agence Nationale de Recherches sur le Sida (ANRS). The ART Cohort Collaboration is funded by the UK Medical Research Council.",

year = "2007",

month = dec,

day = "1",

doi = "10.1086/522986",

language = "English (US)",

volume = "45",

pages = "1518--1521",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "11",

}

TY - JOUR

T1 - Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

AU - Brinkhof, Martin W.G.

AU - Egger, Matthias

AU - Boulle, Andrew

AU - May, Margaret

AU - Hosseinipour, Mina

AU - Sprinz, Eduardo

AU - Braitstein, Paula

AU - Dabis, François

AU - Reiss, Peter

AU - Bangsberg, David R.

AU - Rickenbach, Martin

AU - Miro, Jose M.

AU - Myer, Landon

AU - Mocroft, Amanda

AU - Nash, Denis

AU - Keiser, Olivia

AU - Pascoe, Margaret

AU - Van Der Borght, Stefaan

AU - Schechter, Mauro

AU - Brinkhof, Martin

N1 - Funding Information: Potential conflicts of interest. M.M. has received travel grants from GlaxoSmithKline. P.R. has received research funding from Boehringer-In-gelheim and Merck and has received honoraria for speaking engagements or advisory board participation from Gilead Sciences, Boehringer-Ingel-heim, Roche, Tibotec, GlaxoSmithKline, and Theratechnologies. J.M.M. has received recent research funding or honoraria as speaker/consultant from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Chiron, Cubist, Merck, Novartis, GlaxoSmithKline, Gilead Sciences, Oxford Immunotec, Pfizer, Roche, and Theravance. A.M. has received a consultancy honorarium from Bristol-Myers Squibb. All other authors: no conflicts. Funding Information: Financial support. The ART-LINC Collaboration is funded by the US National Institutes of Health (Office of AIDS Research) and the French Agence Nationale de Recherches sur le Sida (ANRS). The ART Cohort Collaboration is funded by the UK Medical Research Council.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - We examined the incidence of and risk factors for tuberculosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the incidence of tuberculosis associated with highly active antiretroviral therapy was similar: the rate ratio for months 7-12 versus months 1-3 was 0.48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings.

AB - We examined the incidence of and risk factors for tuberculosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the incidence of tuberculosis associated with highly active antiretroviral therapy was similar: the rate ratio for months 7-12 versus months 1-3 was 0.48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings.

UR - http://www.scopus.com/inward/record.url?scp=38449116968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449116968&partnerID=8YFLogxK

U2 - 10.1086/522986

DO - 10.1086/522986

M3 - Article

C2 - 17990236

AN - SCOPUS:38449116968

VL - 45

SP - 1518

EP - 1521

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 11

ER -

Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this